Abstract
Listeria monocytogenes is highly susceptible to meropenem in vitro, but data on the efficacy of meropenem in clinical cases of listeriosis are scarce. Described here is the case of a child with aplastic anemia who acquired nosocomial listeriosis and failed to respond to initial meropenem therapy. Resolution of fever was not noted after 5 days of therapy with meropenem and, more importantly, clinical worsening was observed during this period. The patient began to improve after ampicillin was introduced to the therapeutic regimen. In total, meropenem was administered for 15 days and ampicillin for 10 days.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Doganay M (2003) Listeriosis: clinical presentation. FEMS Immunol Med Microbiol 35:173–175
Hof H, Nichterlein T, Kretschmar M (1997) Management of listeriosis. Clin Microbiol Rev 10:345–357
Carryn S, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM (2002) Comparative intracellular (THP-1 macrophage) and extracellular activities of beta-lactams, azithromycin, gentamicin, and fluoroquinolones against Listeria monocytogenes at clinically relevant concentrations. Antimicrob Agents Chemother 46:2095–2103
Marco F, Almela M, Nolla-Salas J, Coll P, Gasser I, Ferrer MD, de Simon M (2000) In vitro activities of 22 antimicrobial agents against Listeria monocytogenes strains isolated in Barcelona, Spain. The Collaborative Study Group of Listeriosis of Barcelona. Diagn Microbiol Infect Dis 38:259–261
Cometta A, Calandra T, Gaya H, Zinner SH, de Bock R, Del Favero A, Bucaneve G, Crokaert F, Kern WV, Klastersky J, Langenaeken I, Micozzi A, Padmos A, Paesmans M, Viscoli C, Glauser MP (1996) Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 40:1108–1115
Gaya H (1997) Carbapenems in febrile neutropenic patients. J Antimicrob Chemother 39:667–668
Immunocompromised Host Society (1990) The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel. J Infect Dis 161:397–401
Quagliarello VJ, Scheld WM (1997) Treatment of bacterial meningitis. N Engl J Med 336:708–716
Hof H (2003) Therapeutic options. FEMS Immunol Med Microbiol 35:203–205
Carryn S, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM (2003) Activity of beta-lactams (ampicillin, meropenem), gentamicin, azithromycin and moxifloxacin against intracellular Listeria monocytogenes in a 24 h THP-1 human macrophage model. J Antimicrob Chemother 51:1051–1052
Vicente MF, Perez-Daz JC, Baquero F, Angel de Pedro M, Berenguer J (1990) Penicillin-binding protein 3 of Listeria monocytogenes as the primary lethal target for beta-lactams. Antimicrob Agents Chemother 34:539–542
Pierre J, Boisivon A, Gutmann L (1990) Alteration of PBP 3 entails resistance to imipenem in Listeria monocytogenes. Antimicrob Agents Chemother 34:1695–1698
Hof H, Waldenmeier G (1988) Therapy of experimental listeriosis—an evaluation of different antibiotics. Infection 16(Suppl 2):171–174
Nairn K, Shepherd GL, Edwards JR (1995) Efficacy of meropenem in experimental meningitis. J Antimicrob Chemother 36(Suppl A):73–84
Weston VC, Punt J, Vloebeghs M, Watson AR, Ispahani P (1998) Listeria monocytogenes meningitis in a penicillin-allergic paediatric renal transplant patient. J Infect 37:77–78
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stepanović, S., Lazarević, G., Ješić, M. et al. Meropenem therapy failure in Listeria monocytogenes infection. Eur J Clin Microbiol Infect Dis 23, 484–486 (2004). https://doi.org/10.1007/s10096-004-1135-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-004-1135-3